The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or CR with incomplete blood count recovery following intensive induction chemotherapy and who are not able to complete intensive curative therapy.
Essenlix Corporation announced the development of the world’s smallest, simplest, and lowest-cost blood count device – iMOST-CBC (instant mobile self-test for complete blood count).
